AU2009251816B2 - Methods and compositions for sleep disorders and other disorders - Google Patents

Methods and compositions for sleep disorders and other disorders Download PDF

Info

Publication number
AU2009251816B2
AU2009251816B2 AU2009251816A AU2009251816A AU2009251816B2 AU 2009251816 B2 AU2009251816 B2 AU 2009251816B2 AU 2009251816 A AU2009251816 A AU 2009251816A AU 2009251816 A AU2009251816 A AU 2009251816A AU 2009251816 B2 AU2009251816 B2 AU 2009251816B2
Authority
AU
Australia
Prior art keywords
formula
compound
disorders
patient
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009251816A
Other languages
English (en)
Other versions
AU2009251816A1 (en
Inventor
Allen A. FIENBERG
Sharon Mates
Lawrence P. Wennogle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41377435&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009251816(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of AU2009251816A1 publication Critical patent/AU2009251816A1/en
Priority to AU2015218433A priority Critical patent/AU2015218433B2/en
Application granted granted Critical
Publication of AU2009251816B2 publication Critical patent/AU2009251816B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Agronomy & Crop Science (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2009251816A 2008-05-27 2009-05-27 Methods and compositions for sleep disorders and other disorders Active AU2009251816B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015218433A AU2015218433B2 (en) 2008-05-27 2015-08-25 Methods and compositions for sleep disorders and other disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5643308P 2008-05-27 2008-05-27
US61/056,433 2008-05-27
US15503209P 2009-02-24 2009-02-24
US61/155,032 2009-02-24
PCT/US2009/003261 WO2009145900A1 (en) 2008-05-27 2009-05-27 Methods and compositions for sleep disorders and other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015218433A Division AU2015218433B2 (en) 2008-05-27 2015-08-25 Methods and compositions for sleep disorders and other disorders

Publications (2)

Publication Number Publication Date
AU2009251816A1 AU2009251816A1 (en) 2009-12-03
AU2009251816B2 true AU2009251816B2 (en) 2015-12-10

Family

ID=41377435

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009251816A Active AU2009251816B2 (en) 2008-05-27 2009-05-27 Methods and compositions for sleep disorders and other disorders

Country Status (9)

Country Link
US (10) USRE48839E1 (enExample)
EP (2) EP3085231A1 (enExample)
JP (2) JP6106361B2 (enExample)
KR (4) KR102133073B1 (enExample)
CN (2) CN105168219B (enExample)
AU (1) AU2009251816B2 (enExample)
CA (1) CA2725342C (enExample)
MX (3) MX377802B (enExample)
WO (1) WO2009145900A1 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
CN101796051B (zh) 2007-03-12 2013-11-06 细胞内治疗公司 与取代的杂环稠合的γ-咔啉的合成
PL2262505T3 (pl) 2008-03-12 2015-04-30 Intra Cellular Therapies Inc Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej
CN105168219B (zh) * 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
KR101859409B1 (ko) 2009-10-23 2018-05-18 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로［3,4-ｃ］피롤
MX339805B (es) * 2010-04-22 2016-06-10 Intra Cellular Therapies Inc Compuestos organicos.
US8741888B2 (en) * 2010-11-09 2014-06-03 Carl A. Forest Sleep aid composition and method
PL2729474T3 (pl) * 2011-07-08 2018-08-31 Eli Lilly And Company Związki (tieno[2,3-b][1,5]benzoksazepin-ylo)piperazyn-ylowe jako odwrotne agonisty H1/antagonisty 5-HT<sub>2A</sub> o podwójnej aktywności
MX2014012374A (es) 2012-04-14 2015-04-17 Intra Cellular Therapies Inc Compuestos organicos.
CN103175973B (zh) * 2013-02-26 2015-05-13 首都医科大学 甘丙肽在制备女性抑郁症检测工具中的应用
WO2014159720A1 (en) * 2013-03-13 2014-10-02 The University Of Chicago Methods and compositions for inhibiting glyoxalase 1 (glo1)
WO2014152804A1 (en) * 2013-03-14 2014-09-25 Hyperion Biotechnology Methods and compositions for biomarkers of fatigue, fitness and physical performance capacity
WO2014145192A1 (en) 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
EP3076967B1 (en) 2013-12-03 2021-07-28 Intra-Cellular Therapies, Inc. Methods for treating residual symptoms of schizophrenia
CA2944755A1 (en) 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
US10077267B2 (en) * 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
KR20200032759A (ko) * 2015-01-28 2020-03-26 주식회사 제네리스코리아 신경정신계 장애의 치료를 위한 조성물 및 방법
WO2017117514A1 (en) * 2015-12-31 2017-07-06 Tung Roger D Deuterated iti-007
RU2743513C2 (ru) 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
PT3426251T (pt) 2016-03-10 2022-07-27 Janssen Pharmaceutica Nv Métodos de tratamento da depressão utilizando antagonistas dos recetores de orexina-2
JP6686168B2 (ja) 2016-03-25 2020-04-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP3436016B1 (en) 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
JP2019510039A (ja) * 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
WO2017172784A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
WO2018071233A1 (en) 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018126140A1 (en) 2016-12-29 2018-07-05 Intra-Cellular Therapies, Inc. Organic compounds
EP3562484B1 (en) 2016-12-29 2021-08-25 Intra-Cellular Therapies, Inc. Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders
MX387784B (es) 2017-03-24 2025-03-18 Intra Celular Therapies Inc Composiciones novedosas y metodos.
CN110636845A (zh) * 2017-04-10 2019-12-31 雷迪博士实验室有限公司 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体
US9993486B1 (en) 2017-06-19 2018-06-12 Tlc Therapeutics, Llc Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability
CA3071137A1 (en) 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Prodrugs of substituted heterocycle fused gamma-carbolines
IL272249B2 (en) 2017-07-26 2023-11-01 Intra Cellular Therapies Inc Organic compounds
JP2020535231A (ja) * 2017-09-26 2020-12-03 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規な塩および結晶
KR102036909B1 (ko) * 2017-11-28 2019-10-25 한국과학기술원 신규 디스토니아 치료용 약학적 조성물
US11980617B2 (en) 2018-03-16 2024-05-14 Intra-Cellular Therapies, Inc. Methods of treating acute depression and/or acute anxiety
CN112040940A (zh) 2018-03-23 2020-12-04 细胞内治疗公司 有机化合物
IL277509B2 (en) 2018-03-23 2023-11-01 Intra Cellular Therapies Inc Organic compounds
EP3628007B1 (en) 2018-06-06 2023-05-03 Intra-Cellular Therapies, Inc. Novel salts and crystals
CA3102948A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
KR102778034B1 (ko) 2018-06-11 2025-03-12 인트라-셀룰라 써래피스, 인코퍼레이티드. 치환된 헤테로환 융합 감마-카르볼린 합성
CN112585690B (zh) 2018-06-21 2025-04-15 阿奎斯蒂弗医疗股份有限公司 用于制作含有药物活性物质的个性化个体单位剂量的系统和方法
WO2020047241A1 (en) * 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
EP3843738A4 (en) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. NEW METHODS
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CN112955124A (zh) 2018-09-07 2021-06-11 阿奎蒂夫疗法公司 具有精确的活性物溶出谱的口腔膜组合物和剂型
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
EP3898221A4 (en) 2018-12-17 2022-09-14 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND
CA3121631A1 (en) 2018-12-17 2020-06-25 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
MX2021007143A (es) 2018-12-17 2021-08-18 Intra Cellular Therapies Inc Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido.
JP7377871B2 (ja) 2018-12-21 2023-11-10 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP7649743B2 (ja) * 2018-12-21 2025-03-21 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN114072150A (zh) 2019-07-07 2022-02-18 细胞内治疗公司 新方法
US12478623B2 (en) 2019-09-25 2025-11-25 Intra-Cellular Therapies, Inc. Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor
KR102227268B1 (ko) * 2019-10-07 2021-03-12 한국과학기술원 디스토니아 치료 후보 약물의 신규 스크리닝 방법
AU2020373100A1 (en) 2019-11-01 2022-05-19 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
EP4058029B1 (en) 2019-11-14 2025-03-26 Aquestive Therapeutics, Inc. Multimodal compositions and methods of treatment
EP4072554A4 (en) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. ORGANIC COMPOUND
WO2021127572A1 (en) 2019-12-19 2021-06-24 Intra-Cellular Therapies, Inc. Methods of schizophrenia treatment
EP4227306A4 (en) * 2020-10-09 2024-02-28 Shujing Biopharma Co., Ltd HETEROCYCLIC SUBSTITUTED CONDENSED GAMMA-CARBOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, RELATED INTERMEDIATE AND USE THEREOF
WO2022155544A1 (en) 2021-01-15 2022-07-21 Aquestive Therapeutics, Inc. Prodrug compositions and methods of treatment
US20220347117A1 (en) 2021-03-09 2022-11-03 Aquestive Therapeutics, Inc. Dosage forms having equivalent biocomparable profiles
WO2023097316A1 (en) * 2021-11-29 2023-06-01 Editas Medicine, Inc. Engineered crispr/cas12a effector proteins, and uses thereof
US20250195510A1 (en) 2022-05-18 2025-06-19 Intra-Cellular Therapies, Inc. Novel methods
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
CN115067220B (zh) * 2022-06-16 2023-04-25 中国人民解放军军事科学院军事医学研究院 一种双通道小动物恐惧共情行为检测系统
WO2024088285A1 (zh) * 2022-10-26 2024-05-02 上海枢境生物科技有限公司 一种杂环取代的稠合γ-咔啉类衍生物的甲磺酸盐、晶型及其制备方法和应用
AU2023418793A1 (en) 2022-12-30 2025-06-12 Intra-Cellular Therapies, Inc. Heterocycle fused gamma-carbolines acting on the serotonine 5-ht2a receptor
WO2024173901A1 (en) 2023-02-17 2024-08-22 Intra-Cellular Therapies, Inc. Lumateperone and derivatives thereof for modulating the nervous system
WO2025111568A1 (en) 2023-11-22 2025-05-30 Intra-Cellular Therapies, Inc. Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof
KR20250129554A (ko) 2024-02-22 2025-08-29 단국대학교 천안캠퍼스 산학협력단 드로페리돌을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물
WO2025240804A1 (en) 2024-05-16 2025-11-20 Intra-Cellular Therapies, Inc. Novel compositions, devices and methods

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4162318A (en) * 1976-05-05 1979-07-24 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of trazodone and etoperidone in Parkinsonism and in other extrapyramidal syndromes characterized by tremors
HU208484B (en) 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US7071186B2 (en) 1999-06-15 2006-07-04 Bristol-Myers Squibb Pharma Co. Substituted heterocycle fused gamma-carbolines
US6713471B1 (en) 1999-06-15 2004-03-30 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US6548493B1 (en) * 1999-06-15 2003-04-15 Bristol-Myers Squibb Pharma Company Substituted heterocycle fused gamma-carbolines
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
KR20070099031A (ko) * 2005-01-25 2007-10-08 셀진 코포레이션 4-아미노-2-(3-메틸-2,6-디옥소피페리딘-3-일)-이소인돌-1,3-디온을 사용한 방법 및 조성물
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
BRPI0706523A2 (pt) * 2006-01-13 2011-01-04 Wyeth Corp composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
CN101796051B (zh) 2007-03-12 2013-11-06 细胞内治疗公司 与取代的杂环稠合的γ-咔啉的合成
EP2175724A4 (en) 2007-08-01 2010-09-15 Medivation Neurology Inc METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA USING ANTIPSYCHOTIC COMBINATION THERAPY
CA2713935C (en) * 2008-02-07 2016-11-01 Schering Corporation Engineered anti-tslpr antibodies
PL2262505T3 (pl) 2008-03-12 2015-04-30 Intra Cellular Therapies Inc Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
MX339805B (es) 2010-04-22 2016-06-10 Intra Cellular Therapies Inc Compuestos organicos.
MX2014012374A (es) 2012-04-14 2015-04-17 Intra Cellular Therapies Inc Compuestos organicos.
WO2014145192A1 (en) * 2013-03-15 2014-09-18 Intra-Cellular Therapies, Inc. Organic compounds
EP3076967B1 (en) * 2013-12-03 2021-07-28 Intra-Cellular Therapies, Inc. Methods for treating residual symptoms of schizophrenia
US10077267B2 (en) * 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
CA2944755A1 (en) * 2014-04-04 2015-10-08 Intra-Cellular Therapies, Inc. Organic compounds
RU2743513C2 (ru) * 2016-01-26 2021-02-19 Интра-Селлулар Терапиз, Инк. Органические соединения
WO2017172784A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
EP3436016B1 (en) * 2016-03-28 2022-04-27 Intra-Cellular Therapies, Inc. Novel co-crystals
WO2018071233A1 (en) * 2016-10-12 2018-04-19 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
CA3071137A1 (en) * 2017-07-26 2019-01-31 Intra-Cellular Therapies, Inc. Prodrugs of substituted heterocycle fused gamma-carbolines
CA3108558A1 (en) * 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods

Also Published As

Publication number Publication date
US20170189398A1 (en) 2017-07-06
US20200405713A1 (en) 2020-12-31
EP2320731A4 (en) 2012-09-26
JP2015157828A (ja) 2015-09-03
JP6106361B2 (ja) 2017-03-29
US20190183888A1 (en) 2019-06-20
KR102317698B1 (ko) 2021-10-25
US20110071080A1 (en) 2011-03-24
CA2725342C (en) 2024-02-20
CN105168219B (zh) 2018-11-20
JP2011523949A (ja) 2011-08-25
KR102184038B1 (ko) 2020-11-27
MX377802B (es) 2025-03-11
HK1219306A1 (zh) 2017-03-31
US9168258B2 (en) 2015-10-27
CN102105059B (zh) 2015-09-30
US8598119B2 (en) 2013-12-03
US10117867B2 (en) 2018-11-06
KR20110022631A (ko) 2011-03-07
KR20200134341A (ko) 2020-12-01
AU2009251816A1 (en) 2009-12-03
US20140050783A1 (en) 2014-02-20
KR20190006606A (ko) 2019-01-18
KR20160135371A (ko) 2016-11-25
US10702522B2 (en) 2020-07-07
MX2020012868A (es) 2022-06-14
CN105168219A (zh) 2015-12-23
CN102105059A (zh) 2011-06-22
CA2725342A1 (en) 2009-12-03
US20240041871A1 (en) 2024-02-08
US20230355616A1 (en) 2023-11-09
US20160030425A1 (en) 2016-02-04
US20250332164A1 (en) 2025-10-30
EP3085231A1 (en) 2016-10-26
US9616061B2 (en) 2017-04-11
KR102133073B1 (ko) 2020-07-10
WO2009145900A1 (en) 2009-12-03
MX2010013020A (es) 2011-03-21
USRE48839E1 (en) 2021-12-07
EP2320731A1 (en) 2011-05-18

Similar Documents

Publication Publication Date Title
AU2009251816B2 (en) Methods and compositions for sleep disorders and other disorders
CN101983059B (zh) 2,3,4,5- 四氢 -1h- 吡啶并 [4,3-b] 吲哚化合物及其使用方法
AU2017393082B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20090143391A1 (en) Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10
AU2015218433B2 (en) Methods and compositions for sleep disorders and other disorders
HK1230864A1 (en) Method and compositions for sleep disorders and other disorders
HK1219306B (zh) 用於睡眠障碍和其他疾病的方法和组合物
TW200413380A (en) Pyrrolo[1, 2-B]pyridazine compounds and their uses
HK40049071B (zh) 用於治疗认知损害的苯并二氮杂环庚三烯衍生物，组合物和方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)